Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

Bloomsbury Publishing ( ($GB:BMY) ) has shared an announcement. Bloomsbury Publishing has released its Annual Report and Accounts for the year ende...

Bloomsbury Publishes 2026 Annual Report and Sets July AGM

ONO Pharmaceutical Co ($OPHLF), Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. This non-interventional st...

Real-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb has updated a French study that track...

Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a new early-stage trial to...

Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb has completed a real-world study titl...

Bristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market

New Jersey-based cardiovascular biotechnology company Kardigan is set to be valued at up to $1.4 billion in its upcoming U.S. IPO. Heart Disease Dr...

Heart-Disease Biotech Kardigan Set For $1.4B U.S. IPO

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The latest Bristol-Myers Squibb (BMY) update covers a comp...

Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb yesterday. The company’s shares closed yesterday at $54.95. Breen...

Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein

In a report released today, from Jefferies maintained a Buy rating on Bristol-Myers Squibb, with a price target of $73.00. In addition to Jefferies...

Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)

Deutsche Bank analyst reiterated a Buy rating on Bloomsbury Publishing today and set a price target of p760.00. Currently, the analyst consensus on...

Bloomsbury Publishing (BMY) Receives a Buy from Deutsche Bank

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has outlined a new Phase 2 ...

Bristol-Myers Squibb Advances MTAP-Targeted Cancer Trial, Laying Groundwork for Long-Term Oncology Upside

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The Phase 1 study A Phase 1 Study to Evaluate the Safety a...

Bristol-Myers Squibb Backs New Cell Therapy Combo in Early GI Cancer Trial

Shares of Replimune ($REPL) are surging today after the biotech company announced that it plans to resubmit its melanoma drug RP1 for FDA approval ...

Why Penny Stock Replimune (REPL) Nearly Doubled Today

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY) and BridgeBio Pharma (BBI...

Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MacroGenics (MGNX), Bristol-Myers Squibb (BMY) and Pelthos Therap...

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX), Bristol-Myers Squibb (BMY) and Pelthos Therapeutics (PTHS)

Analysts fell to the sidelines weighing in on Bristol-Myers Squibb (BMY), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV) with n...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$54.00	-2.32%	31.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$54.00	-2.3%	31.70M
3
4
5
6

BMY

BMY

No Data Available

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel